Harvard Bioscience Announces Collaboration With NextGen

Harvard Bioscience Inc. and NextGen Sciences Ltd. have announced a collaborative research and development agreement. Harvard Bioscience focuses on developing tools to alleviate critical bottlenecks in the drug discovery process, particularly in the area of protein isolation and ADMET screening. As a result of this research agreement NextGen will develop new applications for the Harvard Read more about Harvard Bioscience Announces Collaboration With NextGen[…]

abbott laboratories

Idun And Abbott Extend Partnership Agreement

Idun Pharmaceuticals, Inc. has extended their worldwide research and development agreement with Abbott Laboratories focusing on the discovery and development of products to treat people with cancer. Under this agreement, Abbott and Idun will continue their collaboration to discover drugs that regulate the activity of specific proteins involved in the cell pathways leading to programmed Read more about Idun And Abbott Extend Partnership Agreement[…]

Qiagen And Zymark Anounce Strategic Alliance

QIAGEN, N.V. and Zymark Corporation have entered into a strategic alliance addressing the use of ultra high-throughput sample and liquid handling automation. The alliance will focus on uses of such instrumentation for nucleic acid handling and purification as well as for QIAGEN’s proprietary protein expression and purification technology. QIAGEN develops and markets liquid handling platforms, Read more about Qiagen And Zymark Anounce Strategic Alliance[…]

XTL Acquires Stake In iviGene

XTL Biopharmaceuticals Ltd has acquired a stake in U.S.-based iviGene Corporation. The acquisition gives XTL access to iviGene‘s proprietary IVIAT technology for identifying novel drug targets for treating a broad range of infectious diseases. The technology is expected to enable XTL to develop both novel human monoclonal antibody and small molecule drugs for antiviral, antibacterial Read more about XTL Acquires Stake In iviGene[…]

Tranxenogen Announces Collaboration With Abbott

TranXenoGen, Inc. has signed a collaborative agreement with Abbott Laboratories to evaluate TranXenoGen’s avian transgenic technology for production of a monoclonal antibody under development at the Abbott Bioresearch Center. The TranXenoGen avian transgenic technology allows for the expression of gene encoding of proteins from cells. As a result, the technology can be used for high-volume Read more about Tranxenogen Announces Collaboration With Abbott[…]

Diversa And Celera Genomics Sequence Streptomyces

Diversa Corporation and Celera Genomics have announced the completion of the entire genome sequence of Streptomyces diversa. The companies completed the sequencing under the collaborative agreement signed in December of 2000. The availability of the genome sequence should enable faster discovery and development of novel molecules of pharmaceutical interest from Diversa’s PathwayLibraries. Diversa‘s proprietary strain, Read more about Diversa And Celera Genomics Sequence Streptomyces[…]

Epimmune Licenses Gene Delivery Technologies

Epimmune Inc. has licensed Valentis, Inc.’s proprietary PINC gene delivery technology for Epimmune’s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Valentis has granted Epimmune a non-exclusive license to certain patented and non-patented technology for use in developing DNA vaccines against HIV and HCV Read more about Epimmune Licenses Gene Delivery Technologies[…]

Protein Sciences And Hts Agree Proteomics Collaboration

Protein Sciences Corporation (PSC) and HTS Biosystems, Inc., have entered into a strategic collaboration to facilitate the discovery of novel protein molecules for the drug and diagnostics markets through innovative solutions for proteomics. This alliance combines PSC’s experience and world leadership in the production of proteins in insect cells with HTS Biosystems’ extensive technology and Read more about Protein Sciences And Hts Agree Proteomics Collaboration[…]

PPGx And Squibb Collaborate On Bioinformatics Software

PPGx, Inc. has announced that Bristol-Myers Squibb Company will incorporate its breakthrough GeneTrials Bioinformatics Platform into its pharmacogenomics research and development program. The agreement is part of PPGx’s GeneTrials Partner Program, a framework through which PPGx grants pharmaceutical and biotechnology companies early access to its bioinformatics technology and pharmacogenomics expertise. Through the program, PPGx software Read more about PPGx And Squibb Collaborate On Bioinformatics Software[…]

Alexion Receives Orphan Drug Status For Dermatomyositis Treatment

The FDA has granted Orphan Drug status to Alexion Pharmaceuticals, Inc.’s humanized monoclonal antibody C5 Complement Inhibitor 5G1.1 for the treatment of patients with dermatomyositis. Alexion is currently enrolling patients in a Phase Ib pilot clinical trial that is designed to gather clinical data regarding the safety profile and biological and clinical effects of 5G1.1 Read more about Alexion Receives Orphan Drug Status For Dermatomyositis Treatment[…]